CClinicalTrials.gg
CompletedNCT05875337Updated Apr 24, 2025

The Effect of Acupressure on Procedural Pain, Anxiety and Hemodynamic Variables During Chest Tube Removal

An interventional study of Acupressure and Placebo acupressure in Pain, Postoperative, Anxiety and Hemodynamic Instability, sponsored by Mersin University. Completed at 1 site in Turkey. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Mersin University · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
68
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

When the literature was reviewed, many studies were found in which various non-pharmacologic interventions such as reflexology, music therapy, slow and deep breathing exercises, relaxation exercises and cold application were examined in the control of pain associated with chest tube removal. However, a limited number of studies have examined the effect of acupressure on the control of pain caused by chest tube removal; there are no studies in which LI4, LI11 and HT7 acupressure points were used and anxiety level and hemodynamic variables were examined along with procedural pain. Thus, the aim of this study was to investigate the effect of acupressure on procedural pain, anxiety and hemodynamic variables after chest tube removal after open heart surgery.

Read the detailed description

Before starting the acupressure/placebo acupressure point application, the area around the area where pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Pressure will be applied to the determined points (LI4, LI11 and HT7 or points 1.5 cm away) with the thumb, index or middle finger manually for 5 seconds to create a depth of 1-1.5 cm, and rest for 2 seconds. Each point will be applied for 2 minutes and the application will last 12 minutes.

When acupressure/plesebo acupressure application is completed, the chest tube will be removed by the physician. Procedural pain level, anxiety level and hemodynamic variables of all patients in the acupressure and placebo acupressure groups will be re-evaluated immediately and 15 minutes after removal of the chest tube.

02

Conditions studied

  • Pain, Postoperative
  • Anxiety
  • Hemodynamic Instability
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's enrollment of 68 is close to the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Mersin University is the lead sponsor of 173 studies on the registry; 48 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • With only one chest tube after open heart surgery,
  • 18 years of age or older,
  • Conscious and cooperative,
  • Speaks and understands Turkish,
  • General condition and hemodynamic variables are stable,
  • Planned surgical intervention,
  • No previous chest tube experience,
  • Acupressure/placebo acupressure without scars, scars, tenderness in the area to be acupressure,
  • No active COVID-19 infection,
  • Does not have any psychiatric diagnosis,
  • Not using psychiatric and/or local neuromuscular blocking drugs,
  • Patients who agreed to participate in the study (signed the Informed Consent Form)

Exclusion criteria

Exclusion Criteria:

  • No chest tube or multiple chest tubes after open heart surgery,
  • Under 18 years of age,
  • Conscious and uncooperative,
  • Speaking Turkish but not understanding it,
  • Unstable general condition and hemodynamic variables,
  • Underwent emergency surgical intervention,
  • Anyone with previous chest tube experience,
  • Wounds, scars, tenderness in the area where acupressure/placebo acupressure will be applied,
  • With active COVID-19 infection,
  • Has an existing psychiatric diagnosis,
  • Psychiatric and/or local neuromuscular blocking drugs,
  • Patients who did not agree to participate in the study (did not sign the Informed Consent Form).
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    Acupressure Group (experimental)

    In the acupressure groups the points are LI4, LI11 and HT7.

    Other: Acupressure

  • Placebo comparator
    Placebo Acupressure Group (control)

    In the placebo acupressure group the points are 1.5 cm away from LI4, LI11 and HT7 points.

    Other: Placebo acupressure

Interventions

  • OtherAcupressure

    Before starting the acupressure point application, the area around the area where the pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Pressure will be applied to the determined points (LI4, LI11 and HT7) with the thumb, index or middle finger manually for 5 seconds to create a depth of 1-1.5 cm and rest for 2 seconds. Each point will be applied for 2 minutes and the application will last 12 minutes.

  • OtherPlacebo acupressure

    Before starting the application to the placebo acupressure point, the area around the area where pressure will be applied for 20-30 seconds will be gently rubbed with the palm of the hand. By gently rubbing the surrounding tissue, tension and tissue sensitivity will be reduced and the tissue will be relaxed by heating, relaxing and preparing the point area. Light pressure will be applied to the determined points (1.5 cm away from LI4, LI11 and HT7 points) with the thumb, index or middle finger. Each point will be applied for 2 minutes and the application will last 12 minutes.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Pain on the Visual Analog Scale at 15 minutes

    The VAS, which is a safe, easily applicable scale tool generally accepted in the literature, consists of a 10 cm long line and subjective descriptive statements at both ends of the scale (0 cm=none and 10 cm=highest degree of presence). The individual marks the appropriate place on the scale on this 10 cm line. The distance from the beginning of the scale to the mark is measured with a ruler and the pain level of the individual is determined numerically in cm.

    Time frame: Baseline and 15 minutes

Secondary outcomes

  1. Change from baseline in Anxiety on the State Anxiety Inventory at 15 minutes

    The total score of the scale is calculated by subtracting the total weighted score of the inverted statements from the total weighted score of the direct statements and adding the number 50, which is the predetermined and unchanging value of the State Anxiety Inventory. A score of 30 and above on this scale indicates moderate anxiety and a score of 45 and above indicates severe anxiety.

    Time frame: Baseline and 15 minutes

  2. Change from baseline in SpO2 at 15 minutes.

    Oxygen saturation measured at the specified times will be recorded for the acupressure and placebo acupressure group patients. Hemodynamic variables will be monitored and recorded with a bedside monitor (Nihon Kohden, Tokyo). To ensure data reliability and accuracy, these monitors are calibrated monthly by the biomedical engineering department as per hospital policy.

    Time frame: Baseline and 15 minutes.

  3. Change from in respiration rate at 15 minutes.

    Respiration rate measured at the specified times will be recorded for the acupressure and placebo acupressure group patients. Hemodynamic variables will be monitored and recorded with a bedside monitor (Nihon Kohden, Tokyo). To ensure data reliability and accuracy, these monitors are calibrated monthly by the biomedical engineering department as per hospital policy.

    Time frame: Baseline and 15 minutes

  4. Change from in systolic blood pressure at 15 minutes

    Systolic blood pressure measured at the specified times will be recorded for the acupressure and placebo acupressure group patients. Hemodynamic variables will be monitored and recorded with a bedside monitor (Nihon Kohden, Tokyo). To ensure data reliability and accuracy, these monitors are calibrated monthly by the biomedical engineering department as per hospital policy.

    Time frame: Baseline and 15 minutes

  5. Change from in diastolic blood pressure at 15 minutes.

    Diastolic blood pressure measured at the specified times will be recorded for the acupressure and placebo acupressure group patients. Hemodynamic variables will be monitored and recorded with a bedside monitor (Nihon Kohden, Tokyo). To ensure data reliability and accuracy, these monitors are calibrated monthly by the biomedical engineering department as per hospital policy.

    Time frame: Baseline and 15 minutes

  6. Change from in heart rate at 15 minutes.

    Heart rate measured at the specified times will be recorded for the acupressure and placebo acupressure group patients. Hemodynamic variables will be monitored and recorded with a bedside monitor (Nihon Kohden, Tokyo). To ensure data reliability and accuracy, these monitors are calibrated monthly by the biomedical engineering department as per hospital policy.

    Time frame: Baseline and 15 minutes

07

Study locations

1 site
  • Mersin University Hospital
    Mersin, Yenişehir 33343, Turkey
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05875337
Lead sponsor
Mersin University
Responsible party
Tugba CAM YANIK (Research Assistant, Mersin University) — Principal investigator
First posted
May 25, 2023
Start date
May 25, 2023
Primary completion
May 25, 2023
Completion
May 25, 2024
Last update
Apr 24, 2025

Study contacts

Gülay ALTUN UĞRAŞ, PhD
study director · Mersin University
Serpil YÜKSEL, PhD
principal investigator · Necmettin Erbakan University
Didem KANDEMİR, PhD
principal investigator · England

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion